Hyaline membrane disease (Respiratory distress syndrome) - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Hyaline Membrane Disease (Respiratory Distress Syndrome) – Comprehensive Guide

Hyaline Membrane Disease (Respiratory Distress Syndrome)

Overview

Hyaline membrane disease (HMD), more commonly called Respiratory Distress Syndrome (RDS) of the newborn, is a lung disorder that occurs most often in premature infants. The disease is characterized by a deficiency of surfactant—a lipoprotein that reduces surface tension in the alveoli—leading to collapse of tiny air sacs, impaired gas exchange, and the formation of a “hyaline” (glass‑like) membrane lining the alveoli.

  • Who it affects: Primarily infants born before 34 weeks of gestation; the risk rises sharply the earlier the birth.
  • Prevalence: In the United States, RDS affects roughly 10 % of all live births, but accounts for up to 40 % of births before 28 weeks. Worldwide, an estimated 1‑2 % of all newborns develop RDS, with higher rates in low‑resource settings where premature delivery is common.1
  • Outcome: With modern neonatal intensive care, survival exceeds 90 % for infants born after 28 weeks; however, morbidity (e.g., chronic lung disease) remains a concern.

Symptoms

Symptoms appear within minutes to a few hours after birth and tend to worsen with each breath. The classic presentation includes:

  • Rapid, shallow breathing (tachypnea): >60 breaths per minute in term infants, >80 in preterm.
  • Chest retractions: Visible pulling of the ribs, sternum, and neck muscles as the infant works harder to inhale.
  • Grunting sound on exhalation: A brief, high‑pitched noise that helps keep alveoli open.
  • Flaring of the nostrils during inspiration.
  • Cyanosis: Bluish tint to lips, tongue, or skin indicating low oxygen.
  • Low blood oxygen (hypoxemia) and low carbon‑dioxide (hypocapnia) levels.
  • Apnea episodes: Brief pauses in breathing, especially in extremely preterm infants.
  • Decreased urine output: A sign of poor perfusion and fluid balance.

Symptoms may be subtle in milder cases, underscoring the importance of vigilant monitoring in any preterm newborn.

Causes and Risk Factors

Underlying cause

RDS results from insufficient pulmonary surfactant**. Surfactant production normally ramps up after 34 weeks of gestation. Without enough surfactant, alveoli collapse (atelectasis), pulmonary compliance falls, and the infant must generate much higher pressures to breathe.

Key risk factors

  • Prematurity: The single most important factor; risk inversely correlates with gestational age.
  • Maternal diabetes: Hyperinsulinemia in the fetus can delay surfactant synthesis.
  • Cesarean delivery without labor: Labor stimulates endogenous surfactant release; elective C‑section before labor increases risk.
  • Male sex: Boys produce surfactant slightly later than girls.
  • Multifetal pregnancy: Higher likelihood of preterm birth.
  • Perinatal asphyxia or hypoxia: Can impair surfactant production.
  • Genetic factors: Mutations affecting surfactant protein genes (SFTPB, SFTPC) are rare but can cause familial RDS.

Diagnosis

Timely diagnosis is critical. Clinicians combine clinical observation with objective testing.

Clinical assessment

  • Observation of respiratory rate, retractions, grunting, and oxygen saturation.
  • Physical exam for signs of cyanosis and apnea.

Radiographic imaging

Chest X‑ray: The classic “ground‑glass” appearance with air bronchograms and low lung volumes. The pattern evolves over the first 24‑48 hours.

Laboratory and bedside tests

  • Blood gas analysis: Shows low PaO₂, low PaCO₂, and metabolic acidosis.
  • Surfactant assay (research setting): Not routinely performed in clinics.
  • Pulse oximetry: Continuous monitoring of oxygen saturation.
  • Transcutaneous CO₂ monitoring: Helpful in neonatal intensive care units (NICUs).

Scoring systems

The Downes' score or the Silverman Anderson score may be used to quantify respiratory distress severity.

Treatment Options

Management focuses on three goals: (1) improve alveolar stability, (2) ensure adequate oxygenation, and (3) minimize ventilator‑induced lung injury.

Surfactant replacement therapy

    <
  • Prophylactic surfactant: Given within 15 minutes of birth to infants < 28 weeks or weighing < 1250 g.
  • Rescue surfactant: Administered when the infant shows worsening oxygen requirements despite CPAP.
  • Common preparations: Beractant (Survanta®), Poractant alfa (Curosurf®), and Calfactant (Infasurf®).
  • Effectiveness: Reduces mortality by ~30 % and incidence of bronchopulmonary dysplasia (BPD).2

Respiratory support

  • Continuous Positive Airway Pressure (CPAP): First‑line for most preterm infants; maintains alveolar pressure and reduces need for intubation.
  • Mechanical ventilation: Required if CPAP fails; modern strategies use low tidal volumes (4‑6 mL/kg) and permissive hypercapnia to limit lung injury.
  • High‑frequency oscillatory ventilation (HFOV): An alternative for severe RDS or when conventional ventilation leads to barotrauma.

Pharmacologic adjuncts

  • Caffeine citrate: Decreases apnea of prematurity and may reduce ventilator days.
  • Inhaled nitric oxide (iNO): Not routinely indicated for RDS alone but considered if persistent pulmonary hypertension develops.
  • Antibiotics: Empiric use if infection is suspected, as sepsis can mimic or worsen RDS.

Supportive measures

  • Thermoregulation (maintaining neutral temperature to reduce metabolic demand).
  • Fluid management: Restrictive fluid strategy to avoid pulmonary edema.
  • Nutrition: Early trophic feeds and parenteral nutrition to support growth.
  • Monitoring for and treating patent ductus arteriosus (PDA) which can exacerbate pulmonary congestion.

Living with Hyaline Membrane Disease (Respiratory Distress Syndrome)

While RDS is a condition of the newborn, families often continue caring for their child after discharge. Practical tips include:

  • Follow‑up appointments: Neonatology visits within the first week, then weekly until the infant is off respiratory support.
  • Vaccinations: Ensure timely immunizations, especially influenza and RSV prophylaxis (palivizumab) for infants < 2 years with a history of severe RDS.
  • Home oxygen: If prescribed, verify correct cylinder/ concentrator use and safety (no smoking, proper ventilation).
  • Growth monitoring: Track weight gain; poor growth may signal ongoing lung disease.
  • Developmental screening: Premature infants are at higher risk for neurodevelopmental delays; early intervention services are beneficial.
  • Family support: Connect with local NICU alumni groups or online forums for emotional support.

Prevention

Because prematurity is the cornerstone risk factor, strategies focus on preventing early birth and optimizing fetal lung maturity.

  • Antenatal corticosteroids: Betamethasone or dexamethasone administered to mothers at risk of delivery before 34 weeks reduces RDS incidence by 40‑50 %.3
  • Timed delivery: Avoid elective cesarean or induction before 39 weeks unless medically indicated.
  • Maternal health: Good glycemic control in diabetic pregnancies, smoking cessation, and treatment of infections.
  • Progesterone therapy: In women with a history of preterm birth, weekly 17‑hydroxyprogesterone caproate can lower premature delivery rates.
  • Neonatal surfactant prophylaxis: For infants known to be extremely preterm, early surfactant administration improves outcomes.

Complications

If RDS is not promptly and adequately treated, several serious complications may arise:

  • Bronchopulmonary dysplasia (BPD): Chronic lung disease characterized by impaired alveolar development; occurs in 20‑40 % of infants requiring >28 days of ventilation.
  • Pneumothorax: Air leaks from over‑distended alveoli, requiring needle decompression or chest tube.
  • Intraventricular hemorrhage (IVH): Fluctuations in cerebral blood flow related to hypoxia.
  • Retinopathy of prematurity (ROP): Linked to oxygen therapy; requires ophthalmologic screening.
  • Neurodevelopmental impairment: Including cerebral palsy, learning deficits, and vision/hearing loss in severe/long‑standing cases.
  • Mortality: Still a leading cause of death in infants < 28 weeks; worldwide neonatal mortality attributable to RDS is estimated at 15‑30 % in low‑resource settings.4

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if a newborn shows any of the following:
  • Severe or worsening rapid breathing (> 80 breaths/min) or visible chest retractions.
  • Persistent grunting or noisy breathing that does not improve with suctioning.
  • Bluish discoloration of the lips, tongue, or skin (cyanosis) that does not resolve with supplemental oxygen.
  • Apnea episodes lasting > 20 seconds, especially if associated with color change or limpness.
  • Sudden drop in oxygen saturation below 85 % despite supplemental oxygen.
  • Any sign of a collapsed lung (one side of the chest looks unusually firm or bulging).

These signs indicate that the infant’s lungs are not providing adequate oxygen and may be in respiratory failure.

Sources:

  1. World Health Organization. Preterm birth fact sheet. 2022.
  2. Jobe AH, et al. Surfactant replacement therapy for newborns with respiratory distress syndrome. New England Journal of Medicine. 2020;382:235‑244.
  3. American College of Obstetricians and Gynecologists. Antenatal corticosteroid therapy. ACOG Committee Opinion No. 713, 2023.
  4. United Nations Inter‑Agency Group for Child Mortality Estimation. Levels & trends in child mortality. 2021.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References